一线PD1抑制剂治疗结外NK/T细胞淋巴瘤的疗效:755例多中心队列比较分析
该回顾性多中心研究纳入755例新诊断结外NK/T细胞淋巴瘤患者,其中17.9%接受一线PD1抑制剂治疗。中位随访32.9个月,PD1抑制剂组无进展生存(HR=0.62,p=0.007)和总生存(HR=0.55,p=0.027)均显著改善,且为独立有利预后因素;联合门冬酰胺酶方案疗效更优,安全性可控。
要点
- 一线PD1抑制剂显著改善PFS(HR=0.62)和OS(HR=0.55),为独立有利预后因素。
- PD1抑制剂联合门冬酰胺酶方案事件概率降低约50%,晚期及中高危患者获益更明显。
- 联合方案血液学毒性增加,但严重/致死性感染风险降低,严重免疫相关不良事件罕见。
核心结论
- 一线PD1抑制剂尤其联合门冬酰胺酶可显著改善中高危和晚期ENKTL患者的结局,安全性可控。
研究设计与样本
- 回顾性多中心队列研究,纳入755例新诊断ENKTL患者,17.9%接受一线PD1抑制剂治疗。
主要发现
- 中位随访32.9个月,PD1抑制剂组PFS显著改善(HR=0.62,p=0.007),OS显著改善(HR=0.55,p=0.027)。
- 亚组分析显示非上呼吸消化道、晚期、中高危患者均获益。
- 多因素Cox回归、倾向性评分匹配后稳健分析及界标分析时变Cox模型均一致表明PD1抑制剂为独立有利预后因素。
- 随机森林算法显示PD1抑制剂联合门冬酰胺酶方案事件概率降低约50%,晚期和中高危患者尤为明显。
- 多状态生存模型提示PD1抑制剂主要延缓疾病进展而非进展后生存。
关键数值与推荐
- PD1抑制剂组PFS的HR=0.62(p=0.007),OS的HR=0.55(p=0.027)。
- PD1抑制剂联合门冬酰胺酶方案事件概率降低约50%。
临床怎么用
- 支持将一线PD1抑制剂尤其联合门冬酰胺酶纳入ENKTL一线治疗,但需前瞻性随机试验验证。
局限性
- 回顾性研究设计,需前瞻性随机试验进一步证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although programmed cell death 1 inhibitors (PD1i) are recommended in guidelines for relapsed/refractory extranodal NK/T-cell lymphoma (ENKTL), their role in frontline therapy remains unclear. In this retrospective, multi-center study of 755 newly diagnosed ENKTL patients, 17.9% received first-line PD1i. Despite harboring more adverse risk features, the PD1i group showed significantly improved progression-free survival (hazard ratio = 0.62, p = 0.007) and overall survival (hazard ratio = 0.55, p = 0.027) after a median follow-up of 32.9 months. The benefit was also observed in key subgroups (non-upper aerodigestive tract, advanced stage, intermediate/high-risk). Conventional multivariate Cox regression before propensity score matching, robust multivariate Cox analysis after matching, and the time-varying Cox model employed in landmark analysis consistently demonstrated that PD1i therapy served as an independent favorable prognostic factor for both progression-free survival and overall survival. The random forest algorithm revealed enhanced efficacy with PD1i-asparaginase combination therapy, showing about a 50% reduction in event probability, particularly in advanced-stage and intermediate/high-risk patients. Multi-state survival modeling indicated PD1i primarily delays disease progression rather than post-progression survival. Safety data showed that adding PD1i to asparaginase-based chemotherapy resulted in an expected increase in hematologic toxicities, but with a reduced risk of severe/fatal infections and rare severe immune-related adverse events, demonstrating a favorable risk-benefit profile. Overall, in this study, frontline PD1i, particularly in combination with asparaginase, yielded significantly improved outcomes and demonstrated a manageable safety profile in intermediate-/high-risk and advanced ENKTL. This evidence supports its incorporation into first-line treatment and underscores the need for prospective randomized trials.
引用
- Liu H, Sun M, Wang C, et al. Outcomes With First-Line PD1 Inhibitors in Extranodal NK/T-Cell Lymphoma: A Comparative Analysis From a 755-Patient Multicenter Cohort. Am J Hematol. 2026. PMID: 42036303. doi:10.1002/ajh.70341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。